Purpose and Research Objectives
The purpose of this award is to recruit and train exceptional physician-scientists from the Osler Medical Residency and the Bayview Internal Medicine Residency Program and to encourage them to remain at Johns Hopkins for fellowship training. The Lou and Nancy Grasmick Scholarship provides up to $50,000 of research support over two years housestaff who remain at Johns Hopkins for fellowship training and are involved in laboratory-based scientific investigation. Funding may be used for research supplies, small equipment (less than $10,000), publication costs and travel for the scholar. This award is NOT to be used to support the salary of the scholar but may be used to support a technician or graduate student to work with the scholar.
- Must be an Osler Medical Resident or Bayview Internal Medicine Resident planning to start a Johns Hopkins fellowship
- Must have a letter of intent to recruit applicant from Johns Hopkins fellowship director that is NOT contingent upon receiving this award
- Letter of recommendation and commitment from research mentor briefly describing potential research project and applicants potential for laboratory-based investigation
- Must have more than 80 percent protected research time during the duration of their award. In fellowship programs with primarily clinical responsibilities in year one, the award can be deferred until year two.
- Prior laboratory-based research is encouraged but not required
2019-2020 Grasmick Scholar
Kristi was born in Silver Spring, Maryland. She studied bioengineering at the University of Pennsylvania where she spent five years researching breast cancer metastasis and recurrence using mouse models of hormone responsive breast cancers. She then went to the University of Maryland to earn her MD and PhD. For her PhD, she worked in Stuart Martin’s lab studying the cytoskeleton of circulating tumor cells in breast cancer. Kristi plans to pursue a fellowship in gastroenterology to focus her research in the field of tumor immunology understanding the effects of checkpoint blockade inhibitors in GI malignancies.